Homepage

Medtronic plc

MDT NYSE Categories PDF
Healthcare · Medical - Devices
Galway, 2, United States IPO 1973 medtronic.com Updated Jun 27, 9:01am
Price
$80.98
Market Cap
$103.7B
Employees
95,000
Beta
0.60
Avg Volume
10,210,553
CEO
Geoffrey Straub Martha
Business Description

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Business History
Price Overview
Last updated: Jun 27, 2026 9:01am (just now)
$80.98
+1.18 (+1.48%)
Day Range
$79.77 – $81.86
52-Week Range
$73.31 – $106.33
50-Day MA
$79.40
200-Day MA
$91.60
Volume
6,968,698.00
Analyst Price Targets
Low $80.00
Consensus $95.80
High $119.00
(96 analysts)
Share Structure
Outstanding 1,280,050,000.00
Float 1,278,835,232.00
Free Float 99.9%
High free float — 99.9% of shares trade freely, ~0.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Last updated: Jun 27, 2026 9:01am (just now)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Jun 23, 2026 3:02am (4d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
API
Stock Price / EPS (Diluted)
21.63
Stock Price: $80.98
EPS (Diluted): 3.75
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
2.16
Stock Price: $80.98
Total Equity: $49.46B
Shares: 1,288,100,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
13.34
Market Cap: $103.66B
Total Debt: $27.96B
Cash: $1.95B
EBITDA: $9.81B
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$132.8B
Market Cap: $103.66B
Total Debt: $27.96B
Cash: $1.95B
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
65.0%
Gross Profit: $23.64B
Revenue: $36.36B
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
17.8%
Operating Income: $6.47B
Revenue: $36.36B
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
13.2%
Net Income: $4.80B
Revenue: $36.36B
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
9.8%
Net Income: $4.80B
Total Equity: $49.46B
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
6.1%
Operating Income: $6.47B
Tax Rate: 21.2%
Equity: $49.46B
Total Debt: $27.96B
Cash: $1.95B
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
2.13
Current Assets: $24.79B
Current Liabilities: $11.66B
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.57
Short-Term Debt: $1.79B
Long-Term Debt: $26.17B
Total Debt: $27.96B
Total Equity: $49.46B
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$28.23
Revenue: $36.36B
Shares: 1,288,100,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$38.40
Total Equity: $49.46B
Shares: 1,288,100,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$4.21
Operating CF: $7.33B
CapEx: -$1.90B
Shares: 1,288,100,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
3.4%
Last Dividend: N/A
Stock Price: $80.98
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $4.80B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MDT against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)
Metric 2022 2023 2024 2025 2026
Revenue $31.7B $31.2B $32.4B $33.5B $36.4B
Cost of Revenue $10.1B $10.7B $11.2B $11.6B $12.7B
Gross Profit $21.5B $20.5B $21.1B $21.9B $23.6B
Operating Expenses $15.8B $15.0B $16.0B $16.0B $17.2B
Operating Income $5.8B $5.5B $5.1B $6.0B $6.5B
Net Income $5.0B $3.8B $3.7B $4.7B $4.8B
EBITDA $8.8B $8.7B $8.2B $9.2B $9.8B
EPS $3.75 $2.83 $2.77 $3.63 $3.75
EPS (Diluted)
Balance Sheet (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)
Metric 2022 2023 2024 2025 2026
Cash & Equivalents $3.7B $1.5B $1.3B $2.2B $1.9B
Total Current Assets $23.1B $21.7B $21.9B $23.8B $24.8B
Total Assets $91.0B $90.9B $90.0B $91.7B $93.0B
Current Liabilities $12.4B $9.1B $10.8B $12.9B $11.7B
Long-Term Debt $20.3B $24.3B $23.9B $25.6B $26.2B
Total Liabilities $38.3B $39.3B $39.6B $43.4B $43.0B
Total Equity $52.6B $51.5B $50.2B $48.0B $49.5B
Retained Earnings $30.3B $30.4B $30.4B $31.5B $32.6B
Cash Flow (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)
Metric 2022 2023 2024 2025 2026
Operating Cash Flow $7.3B $6.0B $6.8B $7.0B $7.3B
Capital Expenditure -$1.4B -$1.5B -$1.6B -$1.9B -$1.9B
Free Cash Flow $6.0B $4.6B $5.2B $5.2B $5.4B
Acquisitions (net) -$91.0M -$1.9B -$211.0M -$98.0M -$406.0M
Debt Repayment
Dividends Paid
Stock Buybacks -$2.5B -$645.0M -$2.1B -$3.2B -$1.0B
Net Change in Cash $121.0M -$2.2B -$259.0M $934.0M -$269.0M
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:01am (just now)
Metric 2028 2029 2030 2031
Revenue $40.0B
$37.3B – $41.0B
$41.7B
$41.6B – $41.8B
$44.2B
$42.1B – $45.1B
$46.6B
$44.3B – $47.5B
EBITDA $10.8B
$10.1B – $11.1B
$11.3B
$11.3B – $11.3B
$12.0B
$11.4B – $12.2B
$12.6B
$12.0B – $12.9B
Net Income $8.3B
$8.1B – $8.5B
$8.7B
$8.1B – $9.3B
$9.8B
$9.2B – $10.1B
$10.6B
$9.9B – $10.9B
EPS
Growth Trends (YoY %)
Last updated: Jun 23, 2026 3:02am (4d ago)
Metric 2023 2024 2025 2026
Revenue Growth -1.4% +3.6% +3.6% +8.4%
Gross Profit Growth -4.8% +3.1% +3.6% +7.9%
Operating Income Growth -4.6% -6.2% +15.8% +8.6%
Net Income Growth -25.4% -2.2% +26.8% +3.0%
EBITDA Growth -0.9% -5.7% +12.4% +6.4%
Insider Trading (Recent)
Type codes PPurchase SSale AAward / grant MOption exercise FIn-kind (tax) CConversion GGift DReturn to issuer
All SEC Form 4 codes
Open market
P Purchase
Open-market or private purchase of shares.
S Sale
Open-market or private sale of shares.
Compensation (Rule 16b-3)
A Award / grant
Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
D Return to issuer
Securities disposed back to the company under Rule 16b-3.
F In-kind (tax)
Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
I Discretionary
Discretionary transaction under an employee plan — Rule 16b-3(f).
M Option exercise
Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
C Conversion
Conversion of a derivative security into the underlying shares.
E Short expiration
Expiration of a short derivative position.
H Long expiration
Expiration or cancellation of a long derivative position with value received.
O OTM exercise
Exercise of an out-of-the-money derivative.
X ITM exercise
Exercise of an in-the-money or at-the-money derivative.
Other exempt
G Gift
Bona fide gift of securities.
L Small acquisition
Small acquisition under Rule 16a-6.
W Inheritance
Acquisition or disposition by will or the laws of descent.
Z Voting trust
Deposit into or withdrawal from a voting trust.
Other
J Other
Other acquisition or disposition (explained in a Form 4 footnote).
K Equity swap
Transaction in an equity swap or similar instrument.
U Tender / buyout
Disposition via tender of shares in a change-of-control transaction.

Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.

Date Insider Type Shares Price Value
2026-06-18 Thompson Kweli 0.00 $0.00 $0
2026-06-18 Thompson Kweli 3,252.99 $0.00 $0
2026-06-18 Thompson Kweli 9,178.81 $0.00 $0
2017-08-01 Thompson Kweli 1,704.00 $88.06 $150,054
2018-01-30 Thompson Kweli 1,608.00 $74.67 $120,069
2018-07-31 Thompson Kweli 4,407.00 $83.97 $370,056
2019-07-30 Thompson Kweli 6,271.00 $89.08 $558,621
2020-07-29 Thompson Kweli 1,615.00 $103.26 $166,765
2021-08-03 Thompson Kweli 10,181.00 $97.33 $990,917
2022-08-02 Thompson Kweli 6,358.00 $131.26 $834,551
2023-08-01 Thompson Kweli 26,890.00 $93.08 $2.5M
2024-07-31 Thompson Kweli 25,408.00 $87.76 $2.2M
2025-07-29 Thompson Kweli 1,540.00 $80.00 $123,200
2026-07-28 Thompson Kweli 22,363.00 $91.97 $2.1M
2026-06-08 KIIL HARRY SKIP S-Sale 3,961.00 $80.44 $318,623
2026-06-08 KIIL HARRY SKIP S-Sale 228.00 $80.45 $18,343
2026-06-04 KIIL HARRY SKIP F-InKind 6,817.00 $83.32 $567,992
2026-06-04 Martha Geoffrey F-InKind 41,936.00 $83.32 $3.5M
2026-06-04 Marinaro Michael F-InKind 7,471.00 $83.32 $622,484
2026-06-04 Walter Matthew R. F-InKind 2,840.00 $83.32 $236,629
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:40pm (5d ago)
Date Dividend Declaration Record Payment
2026-06-26 $0.72 2026-06-03 2026-06-26 2026-07-17
2026-03-27 $0.71 2026-03-05 2026-03-27 2026-04-17
2025-12-26 $0.71 2025-12-04 2025-12-26 2026-01-16
2025-09-26 $0.71 2025-08-14 2025-09-26 2025-10-17
2025-06-27 $0.71 2025-05-20 2025-06-27 2025-07-11
2025-03-28 $0.70 2025-03-06 2025-03-28 2025-04-11
2024-12-27 $0.70 2024-12-05 2024-12-27 2025-01-10
2024-09-27 $0.70 2024-08-15 2024-09-27 2024-10-11
2024-06-28 $0.70 2024-05-22 2024-06-28 2024-07-12
2024-03-21 $0.69 2024-03-07 2024-03-22 2024-04-12
2023-12-19 $0.69 2023-12-07 2023-12-20 2024-01-12
2023-09-21 $0.69 2023-08-17 2023-09-22 2023-10-13
2023-06-22 $0.69 2023-05-24 2023-06-23 2023-07-14
2023-03-23 $0.68 2023-03-02 2023-03-24 2023-04-14
2022-12-20 $0.68 2022-12-08 2022-12-21 2023-01-13
2022-09-22 $0.68 2022-08-18 2022-09-23 2022-10-14
2022-06-23 $0.68 2022-05-25 2022-06-24 2022-07-15
2022-03-24 $0.63 2022-03-03 2022-03-25 2022-04-22
2021-12-21 $0.63 2021-12-09 2021-12-22 2022-01-14
2021-09-23 $0.63 2021-08-20 2021-09-24 2021-10-15
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MDT — it's generated by the pipeline (market-narrative step).
Community AI Feedback
No community reviews yet for MDT. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30